Summary by Moomoo AI
On August 2, 2024, Viva Biotech Holdings ("the Company") submitted its latest monthly securities turnover report to Hong Kong Exchanges and Clearing Limited, reporting on the changes in the Company's shareholding as of July 31, 2024. The report shows that the Company's statutory/registered share capital and issued shares (excluding treasury shares) remained unchanged during the reporting period, with 4,000,000,000 ordinary shares with a par value of $0.000025 per share, and a total statutory/registered share capital of $100,000. In addition, the number of share options for the Company's share option plans, the Pre-IPO Share Incentive Plan and Post-IPO Share Option Plan, remained unchanged at 3,665,141 shares and 26,480,000 shares, respectively. No share options were exercised or any changes in treasury shares during the month. The Company confirms that all securities issuance or sale/transfer of treasury shares have been officially authorized and approved by the Board of Directors, and comply with all applicable listing rules, laws and other regulatory requirements.
